SCHEMBL20147535

SCHEMBL20147535

CC(C)N1CCC(C)(NC(=O)c2ccccc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.49
CYP2D6 P10635 1/20 0.47
TRPV4 Q9HBA0 1/20 0.47
MCHR1 Q99705 1/20 0.44
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
FAAH O00519 1/20 0.41
ALDH1A1 P00352 3/20 0.41
CHRM1 P11229 1/20 0.41
HTT P42858 2/20 0.40
KMT2A Q03164 2/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP1A2 P05177 1/20 0.40
HPGD P15428 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20152063 0.92 ATM (0.47) ATMCYP2D6TRPV4MCHR1HDAC3
SCHEMBL20147564 0.86 CYP2D6 (0.43) CYP2D6HRH3ALDH1A1HPGDCCR1
SCHEMBL20147571 0.84 CHRNA1 (0.48) CYP2D6KMT2ACYP1A2HPGDCYP2C19
SCHEMBL20147648 0.84 TSHR (0.48) HDAC1HDAC6ALDH1A1HTTKMT2A
SCHEMBL20147574 0.84 CYP2D6 (0.48) CYP2D6HDAC1HDAC6ALDH1A1MAPT
SCHEMBL16565618 0.83 ATM (0.49) ATMMCHR1FAAHALDH1A1HTT
SCHEMBL20147586 0.83 KMT2A (0.53) MCHR1FAAHALDH1A1KMT2AMAPT
SCHEMBL12987195 0.82 FAAH (0.51) ATMHDAC3HDAC1HDAC2HDAC6
SCHEMBL20147557 0.82 MCHR1 (0.43) ATMMCHR1HDAC1KMT2A
SCHEMBL20069691 0.82 FAAH (0.46) ATMMCHR1HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2021-01-05 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10881652-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 ATM 753/4885CYP2D6 3759/4885TRPV4 3208/4885
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 ATM 753/4885CYP2D6 3759/4885TRPV4 3208/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 ATM 753/4885CYP2D6 3759/4885TRPV4 3208/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 ATM 753/4885CYP2D6 3759/4885TRPV4 3208/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 ATM 753/4885CYP2D6 3759/4885TRPV4 3208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.